Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK
Oskar Eklund,1 Faraz Afzal,2 Fredrik Borgström,1 Jason Flavin,3 Andrew Ternouth,4 Maria Eugenia Ojanguren,5 Carlos Crespo,5 Mike Baldwin6 1Quantify Research AB, Stockholm, Sweden; 2Boehringer Ingelheim, Asker, Norway; 3Boehringer Ingelheim, Burlington, ON, Canada; 4Boehringer Ingelheim, Bra...
Main Authors: | Eklund O, Afzal F, Borgström F, Flavin J, Ternouth A, Ojanguren ME, Crespo C, Baldwin M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-06-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/cost-effectiveness-of-tiotropium-versus-glycopyrronium-in-moderate-to--peer-reviewed-article-CEOR |
Similar Items
-
Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
by: Kaplan A, et al.
Published: (2019-01-01) -
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01) -
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
by: Marin JM, et al.
Published: (2016-06-01) -
Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
by: Sang Haak Lee, et al.
Published: (2021-04-01) -
Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
by: Hoogendoorn M, et al.
Published: (2019-02-01)